Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ted William Johnson"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Romelia Salomon-Ferrer, Lawrence G. Lum, Todd VanArsdale, Nathan V. Lee, Andrew C. Wang, Aihua Zou, Koleen Eisele, Eric C. Greenwald, Catherine M. Ambler, Ana Flores-Bojorquez, Bryan Li, Carl Davis, Sergei Timofeevski, Martha A. Ornelas, Zhenxiong Wang, Penney L. Khamphavong, Samantha Elizabeth Greasley, Indrawan James Mcalpine, Michael F. Maestre, Jian Li, Ben Bolaños, Neil B. Grodsky, Yun Huang, Stephanie Scales, Ted William Johnson, Roksolana Melnychuk, Wade Diehl, Jon Oyer, Jacob DeForest, Sherry Niessen
Publikováno v:
Cancer Research. 81:330-330
Nomination of new oncology targets has been greatly aided by advances in genetic screening and profiling, but developing potent, selective small molecule inhibitors against these targets remains a resource intensive pursuit. To significantly de-risk
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr
Autor:
Wenyue Hu, Rosa L. Frias, Hovhannes J. Gukasyan, Alice T. Shaw, Valeria Fantin, Ryohei Katayama, Nathan V. Lee, Ruth W. Tang, Timothy Affolter, Eugene Lifshits, Ted William Johnson, Divya Bezwada, David P. Kodack, Lars D. Engstrom, Hieu Lam, Sidra Mahmood, Tod Smeal, Luc Friboulet, Rakesh K. Jain, Hui Wang, Melissa West, Dac M. Dinh, Bhushankumar Patel, Qiuhua Li, Konstantinos Tsaparikos, Helen Y. Zou, Justine L. Lam, Sergei Timofeevski, Shinji Yamazaki, Patrick B. Lappin, Justin F. Gainor, Shibing Deng, Jinwei Wang
Publikováno v:
Cancer Cell. 28:70-81
SummaryWe report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mut
Autor:
Jean E. Lachowicz, Peter J. Tonge, Victor A. Levin, Wang Shen, Timothy P. Heffron, Marc R. Birtwistle, Forest M. White, Russell C. Petter, Antonio Iavarone, Arvin C. Dar, William F. Elmquist, Jann N. Sarkaria, James M. Gallo, Ramakrishna Samala, Donald A. Berry, Quentin R. Smith, Patrick Y. Wen, Patrick J. Paddison, Joohee Sul, Ted William Johnson
Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25aad429e1cfd90fd20f9337a1f568dc
https://europepmc.org/articles/PMC4581696/
https://europepmc.org/articles/PMC4581696/
Autor:
Ganesh Umapathy, Ruth H. Palmer, Yann Jamin, B. Witek, Louis Chesler, Damini Chand, L. Danielson, Jikui Guan, Tod Smeal, E. Tucker, Ted William Johnson, Kristina Ruuth, A. El Wakil, B. Hallberg
Publikováno v:
Cancer Research. 76:B12-B12
ALK inhibitors such as the ALK/MET/ROS1 inhibitor crizotinib (Xalkori) have shown clinical efficacy in a number of tumour types. However, in ALK positive neuroblastoma treatment with the ALK inhibitor crizotinib has proved more difficult, highlightin
Autor:
Luc Friboulet, Tod Smeal, Konstantinos Tsaparikos, Jinwei Wang, Rakesh K. Jain, Hovhannes J. Gukasyan, Valeria Fantin, Qiuhua Li, Helen Y. Zou, Nathan V. Lee, Timothy Affolter, Melissa West, Patrick B. Lappin, Lars D. Engstrom, Sergei Timofeevski, Ted William Johnson, Eugene Lifshits, Justine L. Lam, Hui Wang, Dac M. Dinh, Bhushankumar Patel, David P. Kodack, Hieu Lam, Sidra Mahmood, Shibing Deng, Shinji Yamazaki, Divya Bezwada, Alice T. Shaw, Wenyue Hu, Ruth W. Tang
Publikováno v:
Cancer Research. 75:130-130
Overcoming resistance to targeted kinase inhibitors is a major clinical challenge in oncology. For 1st and 2nd generation ALK inhibitors acquired resistance due to ALK kinase domain mutations and/or pharmacological drug resistance are major causes fo
Autor:
Helen Y. Zou, Konstantinos Tsaparikos, Hui Wang, Nathan V. Lee, Justine L. Lam, Qiuhua Li, Ruth W. Tang, Sergei Timofeevski, Tod Smeal, Valeria Fantin, Shinji Yamazaki, Ted William Johnson, Melissa West Lu, Lars R. Engstrom, Hovhannes J. Gukasyan, Wenyue Hu
Publikováno v:
Molecular Cancer Therapeutics. 12:A277-A277
The oncogenic ROS1 gene fusion (Fig-ROS1) was first identified in glioblastoma cells over two decades ago. Recently, ROS1 gene rearrangements were further discovered in a variety of human cancers, including lung adenocarcinoma, cholangiocarcinoma, ov
Autor:
Jinwei Wang, Sergei Timofeevski, Hovhannes J. Gukasyan, Helen Y. Zou, Wenyue Hu, Konstantinos Tsaparikos, Tod Smeal, Qiuhua Li, Hieu Lam, Shinji Yamazaki, Dac M. Dinh, Justine L. Lam, Timothy Affolter, Ted William Johnson, Lars R. Engstrom, Melissa West Lu, Nathan V. Lee, Valeria Fantin, Patrick B. Lappin, Ruth W. Tang, Hui Wang, Jennifer M. Tursi
Publikováno v:
Molecular Cancer Therapeutics. 12:C253-C253
Oncogenic fusions of Anaplastic Lymphoma Kinase (ALK) define a subset of human lung adenocarcinomas. The 1st generation ALK inhibitor XALKORI ® (crizotinib) demonstrated impressive clinical benefit in ALK-fusion positive lung cancers and was approve
Autor:
Michael R. Collins, Cynthia Louise Palmer, Robert Steven Kania, Neal W. Sach, Mingying He, Phuong Le, Jacqui Elizabeth Hoffman, Ted William Johnson, Helen Y. Zou, Judy G. Deal, Michele McTigue, Benjamin J. Burke, Tod Smeal, Robert Louis Hoffman, Qinhua Huang, Graham L. Smith, J. Jean Cui, Paul F. Richardson, Justine L. Lam, Martin Paul Edwards, Lars D. Engstrom, Ya-Li Deng, Wenyue Hu, Simon Bailey, Hieu Lam
Publikováno v:
Molecular Cancer Therapeutics. 12:PR10-PR10
Oncogenic fusions of anaplastic lymphoma kinase (ALK) define a subset of human lung adenocarcinoma. The 1st generation ALK inhibitor crizotinib demonstrated impressive clinical benefit in ALK-fusion positive lung cancers and was approved by the FDA f